High levels of circulating GM-CSF+CD4+ T cells are predictive of poor outcomes in sepsis patients: a prospective cohort study

[1]  G. Decavalas,et al.  Severe Sepsis and Septic Shock , 2018 .

[2]  Fang Lin,et al.  Mechanism of C5a-induced immunologic derangement in sepsis , 2017, Cellular &Molecular Immunology.

[3]  Marta Elena Losa-Iglesias,et al.  Footwear used by older people and a history of hyperkeratotic lesions on the foot , 2017, Medicine.

[4]  Zheng Zhang,et al.  Low expression of CXCR1/2 on neutrophils predicts poor survival in patients with hepatitis B virus-related acute-on-chronic liver failure , 2016, Scientific Reports.

[5]  R. Hotchkiss,et al.  Comparison of monocyte human leukocyte antigen-DR expression and stimulated tumor necrosis factor alpha production as outcome predictors in severe sepsis: a prospective observational study , 2016, Critical Care.

[6]  Lianxing Zhao,et al.  Monocyte programmed death ligand-1 expression after 3–4 days of sepsis is associated with risk stratification and mortality in septic patients: a prospective cohort study , 2016, Critical Care.

[7]  R. Bellomo,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[8]  Zheng Zhang,et al.  Complement 5a receptor-mediated neutrophil dysfunction is associated with a poor outcome in sepsis , 2015, Cellular and Molecular Immunology.

[9]  F. Safavi,et al.  Expression of GM-CSF in T Cells Is Increased in Multiple Sclerosis and Suppressed by IFN-β Therapy , 2015, The Journal of Immunology.

[10]  I. Wicks,et al.  GM-CSF as a therapeutic target in inflammatory diseases. , 2013, Molecular immunology.

[11]  S. Devadas,et al.  A novel subset of helper T cells promotes immune responses by secreting GM-CSF , 2013, Cell Death and Differentiation.

[12]  T. van der Poll,et al.  Severe sepsis and septic shock. , 2013, The New England journal of medicine.

[13]  J. Cavaillon,et al.  Bench-to-bedside review: Natural killer cells in sepsis - guilty or not guilty? , 2013, Critical Care.

[14]  Faith H. Brennan,et al.  The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries by inhibiting neutrophil mobilization , 2013, Proceedings of the National Academy of Sciences.

[15]  T. Standiford,et al.  The function of neutrophils in sepsis , 2012, Current opinion in infectious diseases.

[16]  H. Chi,et al.  Inflammasome-Derived IL-1β Regulates the Production of GM-CSF by CD4+ T Cells and γδ T Cells , 2012, The Journal of Immunology.

[17]  R. Weissleder,et al.  Innate Response Activator B Cells Protect Against Microbial Sepsis , 2012, Science.

[18]  F. Safavi,et al.  The encephalitogenicity of TH17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF , 2011, Nature Immunology.

[19]  B. Becher,et al.  RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation , 2011, Nature Immunology.

[20]  Jiyuan Zhang,et al.  Interleukin‐17–producing CD4+ T cells increase with severity of liver damage in patients with chronic hepatitis B , 2010, Hepatology.

[21]  V. Preedy,et al.  Prospective Cohort Study , 2010 .

[22]  T. Baumann,et al.  Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. , 2009, American journal of respiratory and critical care medicine.

[23]  H. Medina-Franco,et al.  Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: a randomized, double-blind, placebo-controlled clinical trial. , 2006, Archives of surgery.

[24]  M. Levy,et al.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference , 2003, Intensive care medicine.

[25]  R. Balk,et al.  SEVERE SEPSIS AND SEPTIC SHOCK , 2000 .

[26]  W. Hop,et al.  Complement Activation in Relation to Capillary Leakage in Children with Septic Shock and Purpura , 1998, Infection and Immunity.

[27]  S. Belknap,et al.  A Randomized Controlled Trial of Filgrastim as an Adjunct to Antibiotics for Treatment of Hospitalized Patients with Community-Acquired Pneumonia , 1998 .

[28]  A. Burgess,et al.  Purification and properties of colony-stimulating factor from mouse lung-conditioned medium. , 1977, The Journal of biological chemistry.